IMPORTANT SAFETY INFORMATION

Serious and possibly permanent heart-related side effects that may lead to congestive heart failure can occur in patients treated with DOXIL^®. Inform your doctor of any history of heart disease, radiation to your chest, or prior chemotherapy. Your doctor may monitor your heart function.

Infusion reactions may also occur during administration. Be sure to tell your doctor if you have any symptoms during infusion, including: flushing, shortness of breath, facial swelling, headaches, chills, back pain, tightness in your chest or throat, dizziness, or lightheadedness. For most patients, these reactions have resolved within several hours to a day once the infusion is stopped, or for some patients with slowing of the infusion rate. However, in some cases, these reactions may be serious and sometimes life threatening, though they are rarely fatal.

DOXIL^® may severely reduce the number of blood cells (red blood cells, white blood cells, and platelets) in your body. Your doctor may adjust or delay your dose of DOXIL^® if this occurs.

Your doctor may adjust your dose of DOXIL^® if you have liver problems.

You should not take DOXIL^® if you are nursing. If you are pregnant or are planning to become pregnant, inform your doctor.

You should not take DOXIL^® if you are allergic to doxorubicin HCl or the components of DOXIL^®.

The most common side effects of DOXIL^® are:

Hand-Foot Syndrome (HFS): Tingling or burning, redness, flaking, bothersome swelling, small blisters, or small sores on palms of hands or soles of feet
Stomatitis: Painful redness, swelling, or sores in the mouth
Fever: A fever of 100.5°F or higher
Neutropenia: Low white blood cell count
Nausea, vomiting, tiredness, weakness, rash, shortness of breath, or mild hair loss

In addition, you may experience loss of appetite, constipation, nerve damage (peripheral neuropathy), or diarrhea. Be sure to tell your doctor immediately if you experience any of these or other symptoms.

DOXIL^® may make the side effects of other anticancer therapies worse when used in combination.

Following administration, DOXIL^® may turn urine and other bodily fluids a reddish-orange color. This is due to the color of DOXIL^® and will go away as the drug leaves the body.

DOXIL^® is a prescription drug.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

Please talk to your doctor or nurse if you have any additional questions regarding DOXIL^®.

Please see full Product Information for more details.

VELCADE^® is a registered trademark of Millennium Pharmaceuticals, Inc.

INDICATIONS

DOXIL^® is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

DOXIL^® is used with VELCADE^® (bortezomib) to treat patients with multiple myeloma who have received at least one prior therapy (other than VELCADE^®).

DOXIL^® is administered intravenously by your healthcare professional.

Home Page

IMPORTANT SAFETY INFORMATION